COMMUNIQUÉS West-GlobeNewswire

Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction
26/12/2025
RAMAT GAN, Israel, Dec. 26, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs targeting oncological and [...]
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
26/12/2025
NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services and pharmacy solutions, today announced that its Board of Directors has authorized a cash [...]
IBA signe un contrat pour l’installation d’une solution Proteus®PLUS à trois salles au Seoul St. Mary’s Hospital
26/12/2025
Louvain-la-Neuve, Belgique, le 26 décembre 2025 - IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’accélération de particules et principal fournisseur de solutions de protonthérapie pour le [...]
IBA signs contract for a three-room Proteus®PLUS solution to be installed at the Seoul St. Mary’s Hospital
26/12/2025
Louvain-La-Neuve, Belgium, December 26, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the [...]
XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
24/12/2025
RAMAT GAN, ISRAEL, Dec. 24, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “ Company ” or “ XTL ”), announced today that it has received a notification letter from The Listing [...]
ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain®
24/12/2025
PORTLAND, Maine, Dec. 24, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity [...]
Profound Medical Corp. Announces Upsize of Private Placement
24/12/2025
TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that it has increased the size of its private placement previously announced [...]
Relapse Risk Increases During the Holidays; Desert Hope Treatment Center Urges Early Support
24/12/2025
LAS VEGAS, Dec. 24, 2025 (GLOBE NEWSWIRE) -- This holiday season, addiction experts at Desert Hope Treatment Center are encouraging individuals in recovery to stay connected to support, as research shows drug and [...]
LULUTOX Detox Tea in Consumer Coverage as Website Update Introduces More Transparency in Herbal Digestive Supplement Information
24/12/2025
A summary of the current discussions in consumer health and wellness on the topic of LULUTOX Detox Tea New York City, NY, Dec. 24, 2025 (GLOBE NEWSWIRE) -- With the ongoing popularity of digestive wellness and daily [...]
Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for Future Growth
24/12/2025
Vancouver, Canada, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel [...]
Picard Medical Announces Up to $50 Million Senior Secured Debt Financing
24/12/2025
TUCSON, Ariz., Dec. 24, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved [...]
WORK Medical Technology Group LTD Announces 1-for-100 Reverse Stock Split Effective December 29, 2025
24/12/2025
Hangzhou, China, Dec. 24, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) [...]
MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings
24/12/2025
Purchases reflect strong confidence in the scientific differentiation and commercial potential of ateganosine CHICAGO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “ [...]
PharmAla Issues Audited Year End 2025 and Unaudited Q1 Fiscal 2026 Financial Statements
24/12/2025
TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of [...]
S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive
24/12/2025
The two updates underscore Teva’s strong execution of its Pivot to Growth strategy and commitment to financial discipline. Moody's affirmed Teva's B1a rating and revised Teva's outlook to positive from stable S&P [...]
Human Appeal launches e-greeting card collection to support emergency charity projects
24/12/2025
New feature enables charity to respond faster to emergencies MANCHESTER, United Kingdom, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Leading UK humanitarian aid charity, Human Appeal, today announces the addition of an e-greeting [...]
Communiqué de presse : Sanofi fait le point sur la soumission réglementaire du tolebrutinib dans la sclérose en plaques secondaire progressive non-récurrente
24/12/2025
Sanofi fait le point sur la soumission réglementaire du tolebrutinib dans la sclérose en plaques secondaire progressive non-récurrente Paris, le 24 décembre 2025 . La Food and Drug Administration (FDA) américaine a émis [...]
Press Release: Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis
24/12/2025
Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis Paris, December 24, 2025 . The US Food and Drug Administration (FDA) has issued a complete response [...]
Communiqué de presse : Sanofi va acquérir Dynavax et ajouter un vaccin commercialisé contre l’hépatite B pour adultes et un candidat vaccin de phase 1⁄2 contre le zona au pipeline
24/12/2025
Sanofi va acquérir Dynavax et ajouter un vaccin commercialisé contre l’hépatite B pour adultes et un candidat vaccin de phase 1⁄2 contre le zona au pipeline Paris, le 24 décembre 2025. Sanofi a annoncé aujourd'hui la [...]

Pages